Advanced in Demodicidosis

Dr. Leon Kircik

Dermatology
MSSM-Optical Shop
17 E 102nd St, 
New York, NY 
Advanced in Demodicidosis
MSSM-Optical Shop
17 E 102nd St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leon Kircik is a Dermatologist in New York, New York. Dr. Kircik is rated as an Advanced provider by MediFind in the treatment of Demodicidosis. His top areas of expertise are Acne, Plaque Psoriasis, Atopic Dermatitis, and Psoriasis.

His clinical research consists of co-authoring 357 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Demodicidosis.

Specialties
Dermatology
Licenses
Dermatology in KY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

MSSM-Optical Shop
17 E 102nd St, New York, NY 10029
Call: 212-659-8554
Other Locations
Clinical Pathology Associates
1425 Madison Ave, New York, NY 10029
Call: 212-659-9530

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single Dose Study to Assess the Safety, Pharmacokinetics, and Clinical Effect of CDX-0159 in Patients With Prurigo Nodularis
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug, Biological
Study Drug: CDX-0159
Study Phase: Phase 1
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2019
Intervention Type: Drug
Study Phase: Phase 2
The Use of Oracea and Epiduo Forte in Severe Acne Patients
The Use of Oracea and Epiduo Forte in Severe Acne Patients
Enrollment Status: Completed
Publish Date: April 03, 2019
Intervention Type: Drug
Study Phase: Phase 4
Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris
Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris
Enrollment Status: Completed
Publish Date: April 03, 2019
Intervention Type: Drug
Study Phase: Phase 4
Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis
Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis
Enrollment Status: Completed
Publish Date: March 14, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 15 Less Clinical Trials

355 Total Publications

Maximizing a Focused Vitiligo Patient Visit: A Practical Approach.
Maximizing a Focused Vitiligo Patient Visit: A Practical Approach.
Journal: Journal of drugs in dermatology : JDD
Published: December 02, 2025
View All 355 Publications
Similar Doctors
Advanced in Demodicidosis
Dr. Dawn Queen
Dermatology
Advanced in Demodicidosis
Dr. Dawn Queen
Dermatology

Office

580 Park Ave Ste 1, 
New York, NY 
 (650.6 miles away)
212-752-3692
Languages Spoken:
English
See accepted insurances

Dawn Queen is a Dermatologist in New York, New York. Dr. Queen is rated as an Advanced provider by MediFind in the treatment of Demodicidosis. Her top areas of expertise are Autosomal Recessive Hypotrichosis, Demodicidosis, Lymphomatoid Papulosis, and Cutaneous T-Cell Lymphoma (CTCL).

Dmitriy Timerman
Advanced in Demodicidosis
Dr. Dmitriy Timerman
Dermatology
Advanced in Demodicidosis
Dr. Dmitriy Timerman
Dermatology

Advanced Specialty Care

107 Newtown Road, Suite 2C, 
Danbury, CT 
 (685.9 miles away)
203-830-4700
Languages Spoken:
English
See accepted insurances

Dermatologist Dr. Dmitriy Timerman sees pediatric and adult Dermatology patients. He provides comprehensive dermatological care including evaluation & treatment of acne and other skin conditions such as rashes, skin cancer detection and biopsies.Dr. Timerman has authored 15 peer-reviewed journal articles in dermatology including on psoriasis, atypical skin infections, melanoma, and skin cancer surgery. Dr. Timerman previously practiced in Brooklyn, New York and now lives in Fairfield with his wife and son. In his spare time, he enjoys hiking, gardening, and spending time with his family.Dr. Timerman sees Pediatric and Adult Dermatology patients at Advanced Specialty Care’s Danbury, CT office. Dr. Timerman is rated as an Advanced provider by MediFind in the treatment of Demodicidosis. His top areas of expertise are Contact Dermatitis, Pharyngomaxillary Space Abscess, Pompholyx Eczema, and Plaque Psoriasis.

Advanced in Demodicidosis
Dr. Theodore Daly
Dermatology
Advanced in Demodicidosis
Dr. Theodore Daly
Dermatology

Austin FP

901 Stewart Ave Ste 201, 
Garden City, NY 
 (666.9 miles away)
516-227-3377
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Theodore Daly is a Dermatologist in Garden City, New York. Dr. Daly is rated as a Distinguished provider by MediFind in the treatment of Demodicidosis. His top areas of expertise are GAPO Syndrome, Comedones, Graham-Little-Piccardi-Lassueur Syndrome, and Autosomal Recessive Hypotrichosis.

VIEW MORE DEMODICIDOSIS DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kircik's expertise for a condition
ConditionClose
  • Elite
  • Acne
    Dr. Kircik is
    Elite
    . Learn about Acne.
    See more Acne experts
  • Atopic Dermatitis
    Dr. Kircik is
    Elite
    . Learn about Atopic Dermatitis.
    See more Atopic Dermatitis experts
  • Plaque Psoriasis
    Dr. Kircik is
    Elite
    . Learn about Plaque Psoriasis.
    See more Plaque Psoriasis experts
  • Psoriasis
    Dr. Kircik is
    Elite
    . Learn about Psoriasis.
    See more Psoriasis experts
  • Rosacea
    Dr. Kircik is
    Elite
    . Learn about Rosacea.
    See more Rosacea experts
  • Distinguished
  • Actinic Keratosis
    Dr. Kircik is
    Distinguished
    . Learn about Actinic Keratosis.
    See more Actinic Keratosis experts
  • Athlete's Foot
    Dr. Kircik is
    Distinguished
    . Learn about Athlete's Foot.
    See more Athlete's Foot experts
  • Pustules
    Dr. Kircik is
    Distinguished
    . Learn about Pustules.
    See more Pustules experts
  • Advanced
  • Contact Dermatitis
    Dr. Kircik is
    Advanced
    . Learn about Contact Dermatitis.
    See more Contact Dermatitis experts
  • Demodicidosis
    Dr. Kircik is
    Advanced
    . Learn about Demodicidosis.
    See more Demodicidosis experts
  • Folliculitis
    Dr. Kircik is
    Advanced
    . Learn about Folliculitis.
    See more Folliculitis experts
  • Impetigo
    Dr. Kircik is
    Advanced
    . Learn about Impetigo.
    See more Impetigo experts
  • Molluscum Contagiosum
    Dr. Kircik is
    Advanced
    . Learn about Molluscum Contagiosum.
    See more Molluscum Contagiosum experts
  • Parapsoriasis
    Dr. Kircik is
    Advanced
    . Learn about Parapsoriasis.
    See more Parapsoriasis experts
View All 11 Advanced Conditions
  • Experienced
  • Basal Cell Skin Cancer
    Dr. Kircik is
    Experienced
    . Learn about Basal Cell Skin Cancer.
    See more Basal Cell Skin Cancer experts
  • Bowen's Disease
    Dr. Kircik is
    Experienced
    . Learn about Bowen's Disease.
    See more Bowen's Disease experts
  • Bullae
    Dr. Kircik is
    Experienced
    . Learn about Bullae.
    See more Bullae experts
  • Comedones
    Dr. Kircik is
    Experienced
    . Learn about Comedones.
    See more Comedones experts
  • Epidermodysplasia Verruciformis
    Dr. Kircik is
    Experienced
    . Learn about Epidermodysplasia Verruciformis.
    See more Epidermodysplasia Verruciformis experts
  • Epidermoid Cyst
    Dr. Kircik is
    Experienced
    . Learn about Epidermoid Cyst.
    See more Epidermoid Cyst experts
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.